Browsing Tag
Obsidian Convertible Note Facility
1 post
Paradigm Biopharmaceuticals (ASX: PAR) raises A$14m as Phase 3 osteoarthritis trial enters decisive window
Paradigm Biopharmaceuticals has more cash, but Zilosul still needs Phase 3 proof. ASX:PAR now turns from funding risk to data risk.